We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
Read MoreHide Full Article
Key Takeaways
TG Therapeutics' Briumvi sales rose 52% year over year in Q3 2026, prompting higher revenue guidance.
BioCryst is expanding Orladeyo's reach through pediatric formulations and growing patient adoption.
INSM and MDGL are benefiting from rising product demand, market expansion and potential new indications.
For biotechnology companies, securing regulatory approval is only the first step toward building a sustainable business. Translating approved therapies into consistent revenue growth is equally important, as it demonstrates successful commercialization, growing physician adoption and increasing patient demand. Companies with established marketed products and expanding sales are also better positioned to finance operations and research through internally generated revenues.
However, strong performance in a single quarter does not necessarily establish a sustainable growth trajectory. Investors should assess whether product sales are increasing consistently, supported by broader market penetration, improved patient access, additional indications and international expansion. Companies that combine these factors with growing addressable markets may be better positioned to maintain commercial momentum despite competitive pressures.
Against this backdrop, TG Therapeutics (TGTX - Free Report) , BioCryst Pharmaceuticals (BCRX - Free Report) , Insmed (INSM - Free Report) and Madrigal Pharmaceuticals (MDGL - Free Report) stand out among commercial-stage biotechs. All four have established marketed therapies targeting significant unmet medical needs and are pursuing opportunities to expand their commercial reach. Their focus on increasing product adoption, broadening patient access and strengthening existing franchises provides a foundation for sustained revenue growth. TGTX sports a Zacks Rank #1 (Strong Buy), BCRX has a Zacks Rank #2 (Buy), and INSM and MDGL carry a Zacks Rank #3 (Hold) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
TG Therapeutics
TG Therapeutics' commercial business is centered on Briumvi (ublituximab-xiiy), approved for treating relapsing forms of multiple sclerosis (MS) in adults. Briumvi's U.S. net product revenues increased from $194.8 million in the first quarter of 2026 to $227.7 million in the second quarter, reflecting sequential growth of 17%. Sales rose a further 2% sequentially to $232.6 million in the third quarter, representing a robust 52% increase year over year. Total global revenues reached $259.9 million in the latest reported quarter, up 61% year over year. Strong underlying demand, new patient starts and increasing physician adoption have supported Briumvi's commercial performance.
Briumvi's established efficacy profile and relatively convenient infusion experience support its competitive positioning in the MS market. TG Therapeutics is pursuing dosing innovations to improve treatment convenience and expand the franchise's commercial opportunity. Positive phase III ENHANCE study results support a simplified single-infusion initiation regimen of Briumvi for the MS indication. Meanwhile, a quarterly self-administered subcutaneous formulation of the drug for the same indication is being evaluated in a phase III study, with top-line data expected around year-end 2026 or early 2027. Reflecting continued demand, TG Therapeutics raised its 2026 total global revenue guidance to approximately $1 billion from $950 million and its U.S. Briumvi net product revenue guidance to $915-$920 million from $890-$905 million. Continued market penetration and potential dosing improvements should support future growth.
BioCryst Pharmaceuticals
BioCryst's commercial business is primarily driven by Orladeyo (berotralstat), an oral, once-daily therapy approved for preventing hereditary angioedema (HAE) attacks. Orladeyo net revenues increased from $148.3 million in the first quarter of 2026 to $158.2 million in the second quarter, reflecting approximately 7% sequential growth. Sales rose another 11% to $174.8 million in the third quarter, representing 10% year-over-year growth. Total third-quarter revenues reached $180.3 million, up 13% year over year. Orladeyo's differentiated oral administration and growing adoption among patients requiring long-term HAE prophylaxis have supported its commercial performance. However, third-quarter revenues also benefited from an initial inventory build associated with the transition to a new specialty pharmacy partner, which boosted reported sequential growth.
BioCryst Pharmaceuticals, Inc. Price and Consensus
BioCryst is working to expand Orladeyo's reach through additional formulations and improved patient access. The company began commercial shipments of Orladeyo oral pellets for pediatric patients aged 2 to younger than 12 years in August 2026, while the FDA approved the formulation for patients aged 12 years and older in October. These developments could expand treatment options and support future demand. BioCryst maintained its 2026 Orladeyo revenue guidance of $625-$645 million while raising its total revenue guidance to $715-$730 million from $690-$715 million. The upward revision primarily reflects higher licensing revenues from the European rights to navenibart, an investigational long-acting HAE therapy, and increased international partner orders for Rapivab (peramivir injection), an antiviral treatment for influenza. While these contributions support overall revenues, Orladeyo remains the company's principal commercial growth driver. Continued patient adoption and expanded formulation availability should support Orladeyo's future sales growth.
Insmed
Insmed's commercial portfolio is led by Brinsupri (brensocatib), indicated for treating non-cystic fibrosis bronchiectasis in patients aged 12 years and older, and Arikayce (amikacin liposome inhalation suspension), approved for adults with refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial regimen. Brinsupri revenues increased from $207.9 million in the first quarter of 2026 to $309.2 million in the second quarter and $400.1 million in the third quarter, reflecting sequential growth of 49% and 29%, respectively. Arikayce sales also improved, rising from $98.1 million to $116.3 million and $124.4 million across the three quarters. Total third-quarter revenues reached $524.4 million, up 268% year over year, primarily reflecting Brinsupri's commercialization following its 2025 launch.
Brinsupri's rapid U.S. uptake has been the primary growth driver, supported by increasing patient and physician adoption. Its October 2026 launch in Japan provides an additional international opportunity. Meanwhile, Arikayce's third-quarter sales increased 9% year over year, primarily driven by higher sales in international markets. The FDA has also granted Priority Review to Insmed's supplemental application seeking to expand Arikayce's use beyond refractory MAC lung disease, where patients have failed to respond to at least six months of multidrug therapy. Supported by positive phase IIIb ENCORE results, the proposed label expansion could enable Arikayce to be used in earlier treatment settings, including in newly diagnosed patients and those with recurrent infections. The FDA has set a target decision date of Jan. 28, 2027. Reflecting sustained commercial momentum, Insmed raised the lower end of its 2026 revenue guidance for Brinsupri to $1.35-$1.40 billion from $1.25-$1.40 billion and for Arikayce to $460-$470 million from $450-$470 million. Continued U.S. penetration, Brinsupri's Japanese launch and potential Arikayce label expansion should support further revenue growth.
Madrigal Pharmaceuticals
Madrigal's commercial performance is driven by Rezdiffra (resmetirom), approved alongside diet and exercise for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), with moderate-to-advanced liver fibrosis (F2-F3). Rezdiffra generated net sales of $311.3 million in the first quarter of 2026, up 17% sequentially to $364.3 million in the second quarter. Sales advanced another 18% to $431.3 million in the third quarter, representing 50% year-over-year growth in total revenues. Year-to-date sales reached approximately $1.1 billion, establishing Rezdiffra as a blockbuster therapy. As of Sept. 30, 2026, more than 55,850 patients were receiving Rezdiffra, nearly twice the year-ago level, reflecting increasing physician adoption and strong patient demand.
Madrigal Pharmaceuticals, Inc. Price and Consensus
Madrigal has been expanding its endocrinology sales force and investing in direct-to-consumer promotional activities to strengthen Rezdiffra's market penetration. The addressable U.S. F2-F3 MASH market exceeded 530,000 patients as of June 2026, with the company expecting it to expand more than 30% by year-end. This provides substantial opportunities for continued prescription growth. Madrigal is also advancing Rezdiffra in compensated MASH cirrhosis through its phase III MAESTRO-NASH OUTCOMES study, with data expected in late 2027, while planning to initiate the phase III MAESTRO-CSPH study in the first half of 2027 to further evaluate the therapy's clinical benefits in this patient population, particularly those with clinically significant portal hypertension. Increasing patient penetration, broader market awareness and potential future indication expansions should support Rezdiffra's long-term revenue trajectory.
View the Zacks #1 Rank List
Image: Bigstock
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
Key Takeaways
For biotechnology companies, securing regulatory approval is only the first step toward building a sustainable business. Translating approved therapies into consistent revenue growth is equally important, as it demonstrates successful commercialization, growing physician adoption and increasing patient demand. Companies with established marketed products and expanding sales are also better positioned to finance operations and research through internally generated revenues.
However, strong performance in a single quarter does not necessarily establish a sustainable growth trajectory. Investors should assess whether product sales are increasing consistently, supported by broader market penetration, improved patient access, additional indications and international expansion. Companies that combine these factors with growing addressable markets may be better positioned to maintain commercial momentum despite competitive pressures.
Against this backdrop, TG Therapeutics (TGTX - Free Report) , BioCryst Pharmaceuticals (BCRX - Free Report) , Insmed (INSM - Free Report) and Madrigal Pharmaceuticals (MDGL - Free Report) stand out among commercial-stage biotechs. All four have established marketed therapies targeting significant unmet medical needs and are pursuing opportunities to expand their commercial reach. Their focus on increasing product adoption, broadening patient access and strengthening existing franchises provides a foundation for sustained revenue growth. TGTX sports a Zacks Rank #1 (Strong Buy), BCRX has a Zacks Rank #2 (Buy), and INSM and MDGL carry a Zacks Rank #3 (Hold) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
TG Therapeutics
TG Therapeutics' commercial business is centered on Briumvi (ublituximab-xiiy), approved for treating relapsing forms of multiple sclerosis (MS) in adults. Briumvi's U.S. net product revenues increased from $194.8 million in the first quarter of 2026 to $227.7 million in the second quarter, reflecting sequential growth of 17%. Sales rose a further 2% sequentially to $232.6 million in the third quarter, representing a robust 52% increase year over year. Total global revenues reached $259.9 million in the latest reported quarter, up 61% year over year. Strong underlying demand, new patient starts and increasing physician adoption have supported Briumvi's commercial performance.
TG Therapeutics, Inc. Price and Consensus
TG Therapeutics, Inc. price-consensus-chart | TG Therapeutics, Inc. Quote
Briumvi's established efficacy profile and relatively convenient infusion experience support its competitive positioning in the MS market. TG Therapeutics is pursuing dosing innovations to improve treatment convenience and expand the franchise's commercial opportunity. Positive phase III ENHANCE study results support a simplified single-infusion initiation regimen of Briumvi for the MS indication. Meanwhile, a quarterly self-administered subcutaneous formulation of the drug for the same indication is being evaluated in a phase III study, with top-line data expected around year-end 2026 or early 2027. Reflecting continued demand, TG Therapeutics raised its 2026 total global revenue guidance to approximately $1 billion from $950 million and its U.S. Briumvi net product revenue guidance to $915-$920 million from $890-$905 million. Continued market penetration and potential dosing improvements should support future growth.
BioCryst Pharmaceuticals
BioCryst's commercial business is primarily driven by Orladeyo (berotralstat), an oral, once-daily therapy approved for preventing hereditary angioedema (HAE) attacks. Orladeyo net revenues increased from $148.3 million in the first quarter of 2026 to $158.2 million in the second quarter, reflecting approximately 7% sequential growth. Sales rose another 11% to $174.8 million in the third quarter, representing 10% year-over-year growth. Total third-quarter revenues reached $180.3 million, up 13% year over year. Orladeyo's differentiated oral administration and growing adoption among patients requiring long-term HAE prophylaxis have supported its commercial performance. However, third-quarter revenues also benefited from an initial inventory build associated with the transition to a new specialty pharmacy partner, which boosted reported sequential growth.
BioCryst Pharmaceuticals, Inc. Price and Consensus
BioCryst Pharmaceuticals, Inc. price-consensus-chart | BioCryst Pharmaceuticals, Inc. Quote
BioCryst is working to expand Orladeyo's reach through additional formulations and improved patient access. The company began commercial shipments of Orladeyo oral pellets for pediatric patients aged 2 to younger than 12 years in August 2026, while the FDA approved the formulation for patients aged 12 years and older in October. These developments could expand treatment options and support future demand. BioCryst maintained its 2026 Orladeyo revenue guidance of $625-$645 million while raising its total revenue guidance to $715-$730 million from $690-$715 million. The upward revision primarily reflects higher licensing revenues from the European rights to navenibart, an investigational long-acting HAE therapy, and increased international partner orders for Rapivab (peramivir injection), an antiviral treatment for influenza. While these contributions support overall revenues, Orladeyo remains the company's principal commercial growth driver. Continued patient adoption and expanded formulation availability should support Orladeyo's future sales growth.
Insmed
Insmed's commercial portfolio is led by Brinsupri (brensocatib), indicated for treating non-cystic fibrosis bronchiectasis in patients aged 12 years and older, and Arikayce (amikacin liposome inhalation suspension), approved for adults with refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial regimen. Brinsupri revenues increased from $207.9 million in the first quarter of 2026 to $309.2 million in the second quarter and $400.1 million in the third quarter, reflecting sequential growth of 49% and 29%, respectively. Arikayce sales also improved, rising from $98.1 million to $116.3 million and $124.4 million across the three quarters. Total third-quarter revenues reached $524.4 million, up 268% year over year, primarily reflecting Brinsupri's commercialization following its 2025 launch.
Insmed, Inc. Price and Consensus
Insmed, Inc. price-consensus-chart | Insmed, Inc. Quote
Brinsupri's rapid U.S. uptake has been the primary growth driver, supported by increasing patient and physician adoption. Its October 2026 launch in Japan provides an additional international opportunity. Meanwhile, Arikayce's third-quarter sales increased 9% year over year, primarily driven by higher sales in international markets. The FDA has also granted Priority Review to Insmed's supplemental application seeking to expand Arikayce's use beyond refractory MAC lung disease, where patients have failed to respond to at least six months of multidrug therapy. Supported by positive phase IIIb ENCORE results, the proposed label expansion could enable Arikayce to be used in earlier treatment settings, including in newly diagnosed patients and those with recurrent infections. The FDA has set a target decision date of Jan. 28, 2027. Reflecting sustained commercial momentum, Insmed raised the lower end of its 2026 revenue guidance for Brinsupri to $1.35-$1.40 billion from $1.25-$1.40 billion and for Arikayce to $460-$470 million from $450-$470 million. Continued U.S. penetration, Brinsupri's Japanese launch and potential Arikayce label expansion should support further revenue growth.
Madrigal Pharmaceuticals
Madrigal's commercial performance is driven by Rezdiffra (resmetirom), approved alongside diet and exercise for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), with moderate-to-advanced liver fibrosis (F2-F3). Rezdiffra generated net sales of $311.3 million in the first quarter of 2026, up 17% sequentially to $364.3 million in the second quarter. Sales advanced another 18% to $431.3 million in the third quarter, representing 50% year-over-year growth in total revenues. Year-to-date sales reached approximately $1.1 billion, establishing Rezdiffra as a blockbuster therapy. As of Sept. 30, 2026, more than 55,850 patients were receiving Rezdiffra, nearly twice the year-ago level, reflecting increasing physician adoption and strong patient demand.
Madrigal Pharmaceuticals, Inc. Price and Consensus
Madrigal Pharmaceuticals, Inc. price-consensus-chart | Madrigal Pharmaceuticals, Inc. Quote
Madrigal has been expanding its endocrinology sales force and investing in direct-to-consumer promotional activities to strengthen Rezdiffra's market penetration. The addressable U.S. F2-F3 MASH market exceeded 530,000 patients as of June 2026, with the company expecting it to expand more than 30% by year-end. This provides substantial opportunities for continued prescription growth. Madrigal is also advancing Rezdiffra in compensated MASH cirrhosis through its phase III MAESTRO-NASH OUTCOMES study, with data expected in late 2027, while planning to initiate the phase III MAESTRO-CSPH study in the first half of 2027 to further evaluate the therapy's clinical benefits in this patient population, particularly those with clinically significant portal hypertension. Increasing patient penetration, broader market awareness and potential future indication expansions should support Rezdiffra's long-term revenue trajectory.